 |
|
Multiple Myeloma Trial Results
1. Thalidomide a Beneficial Option for Elderly Multiple Myeloma Patients
(Posted: 02/12/2008) - Patients aged 75 and over with newly diagnosed multiple myeloma who received the drug thalidomide in addition to standard therapy (melphalan and prednisone) survived longer than patients who received standard therapy plus a placebo, according to clinical trial results presented at the 2007 annual meeting of the American Society of Hematology.
2. Drug Combination Shows Benefit in Relapsed/Refractory Multiple Myeloma
(Posted: 08/28/2007) - A new combination treatment should be another standard of care for patients with relapsed or refractory multiple myeloma, according to the Sept. 1, 2007, Journal of Clinical Oncology.
3. Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
(Posted: 04/04/2007) - Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.
4. Study Compares Stem Cell Transplant Treatments
(Posted: 03/21/2007) - Patients with newly diagnosed multiple myeloma who received a transplant of their own stem cells (autologous) and a second stem cell transplant from an HLA-matched sibling (allogeneic) had superior survival outcomes compared to patients who received two autologous stem cell transplants, according to the March 15, 2007, New England Journal of Medicine.
5. Lenalidomide Effective in Multiple Myeloma
(Posted: 06/28/2006, Reviewed: 11/27/2007) - Combining lenalidomide with dexamethasone delayed the progression of advanced multiple myeloma for more than twice as long as did dexamethasone alone in patients whose disease had come back or stopped responding to other treatments, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
1 2 3 4 Next >
|
|
|
